Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Wedbush PacGrow Healthcare Virtual Conference Transcript

Aug 11, 2020 / 02:55PM GMT
Release Date Price: $116.81
Vasiliana Vireen Moussatos
Wedbush Securities Inc., Research Division - MD of Equity Research

Thank you very much for joining us at the 2020 Virtual Wedbush Healthcare Conference. My name is Liana Moussatos, and I'm one of the senior health care analysts at Wedbush. It's my pleasure to introduce our next presenting company, BioMarin Pharmaceuticals, which is on the Wedbush's Best Ideas List. BioMarin is the first company to develop a one-shot-and-done gene therapy cure for hemophilia A and is years ahead of the competition.

Today, we are joined by the CFO, Brian Mueller; and Chief Commercial Officer, Jeff Ajer. Thanks very much for joining us. We will start with a fireside chat and then transition to Q&A. If you would like to ask a question, please submit them through the chat window at the bottom of your screen.

Questions & Answers

Vasiliana Vireen Moussatos
Wedbush Securities Inc., Research Division - MD of Equity Research

So Brian, Jeff, let's start with ROCTAVIAN for hemophilia A. Can you describe the burden of the disease? And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot